Mucin-based targeted pancreatic cancer therapy

María P. Torres, Subhankar Chakraborty, Joshua Souchek, Surinder Kumar Batra

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)2472-2481
Number of pages10
JournalCurrent Pharmaceutical Design
Volume18
Issue number17
StatePublished - Jun 1 2012

Fingerprint

Mucins
Pancreatic Neoplasms
Immunoconjugates
Therapeutics
Tumor Biomarkers
Genetic Therapy
Immunotherapy
Amino Acid Sequence
Glycoproteins
Vaccines
Survival
Antibodies
Proteins

Keywords

  • Mucins
  • Pancreatic cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Torres, M. P., Chakraborty, S., Souchek, J., & Batra, S. K. (2012). Mucin-based targeted pancreatic cancer therapy. Current Pharmaceutical Design, 18(17), 2472-2481.

Mucin-based targeted pancreatic cancer therapy. / Torres, María P.; Chakraborty, Subhankar; Souchek, Joshua; Batra, Surinder Kumar.

In: Current Pharmaceutical Design, Vol. 18, No. 17, 01.06.2012, p. 2472-2481.

Research output: Contribution to journalReview article

Torres, MP, Chakraborty, S, Souchek, J & Batra, SK 2012, 'Mucin-based targeted pancreatic cancer therapy', Current Pharmaceutical Design, vol. 18, no. 17, pp. 2472-2481.
Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Current Pharmaceutical Design. 2012 Jun 1;18(17):2472-2481.
Torres, María P. ; Chakraborty, Subhankar ; Souchek, Joshua ; Batra, Surinder Kumar. / Mucin-based targeted pancreatic cancer therapy. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 17. pp. 2472-2481.
@article{13bd9fa01b2d4f0c86b2960427bd09d2,
title = "Mucin-based targeted pancreatic cancer therapy",
abstract = "The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5{\%}. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.",
keywords = "Mucins, Pancreatic cancer, Targeted therapy",
author = "Torres, {Mar{\'i}a P.} and Subhankar Chakraborty and Joshua Souchek and Batra, {Surinder Kumar}",
year = "2012",
month = "6",
day = "1",
language = "English (US)",
volume = "18",
pages = "2472--2481",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "17",

}

TY - JOUR

T1 - Mucin-based targeted pancreatic cancer therapy

AU - Torres, María P.

AU - Chakraborty, Subhankar

AU - Souchek, Joshua

AU - Batra, Surinder Kumar

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

AB - The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

KW - Mucins

KW - Pancreatic cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84860448397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860448397&partnerID=8YFLogxK

M3 - Review article

VL - 18

SP - 2472

EP - 2481

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 17

ER -